We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys to Receive Milestone Payment for CNTO 1959 Phase 2 Program"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

MorphoSys AG has announced that Janssen Biotech, Inc. (formerly Centocor Ortho Biotech, Inc.) has initiated a phase 2 clinical trial in psoriasis patients with the HuCAL-derived antibody CNTO 1959.

The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.

"With every clinical milestone and every new phase 2 start the time where the first HuCAL-based antibody drug could enter the market gets closer. MorphoSys's antibody pipeline has substantially matured over the last 18 months," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

In total, MorphoSys's clinical pipeline now comprises nine partnered programs in phase 1 and seven in phase 2 development as well as the Company's proprietary programs MOR103, which is in a phase 1b/2a trial for rheumatoid arthritis, MOR208, which is in a phase 1 trial for chronic lymphocytic leukemia and MOR202, which is in a phase 1/2a trial for multiple myeloma.